BRAINSTORM CELL THERAPEUTICS INC. (BCLI): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.2 3 tm2621592d1_ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 BRAINSTORM CELL THERAPEUTIC INC. 2014 STOCK INCENTIVE PLAN STOCK OPTION GRANT NOTICE Brainstorm Cell Therapeutics Inc., a Delaware corporation, (the “ Company ”), pursuant to its 2014 Stock Incentive Plan, as may be amend
How this was made
The 30-second read
Why it matters
This disclosure primarily updates management compensation via a stock option grant, with no direct information on trials, approvals, or financial performance in the provided text.
Market read
For BCLI, the actionable takeaway is the CEO option grant terms (exercise price, share count, vesting), which is typically low-impact versus clinical or financial catalysts.
What to watch
Traders may want to check whether this 8-K also includes director/officer departures or elections beyond the excerpt, since Item 5.02 can bundle multiple governance changes.
Background
The SEC 8-K Item 5.02 covers departures/elections/appointments and compensatory arrangements for certain officers.
Ticker impact
BCLI filed an 8-K for Item 5.02, granting a nonqualified stock option to CEO Peter Pitts with a $1.00 exercise price and 900,000 shares.
Likely limited, with any reaction driven by optics of compensation rather than new financial guidance.
The text provides option grant mechanics (exercise price, share count, vesting) but no new clinical, revenue, or regulatory catalyst.
Market effects
Minimal; equity-compensation disclosures are common in biotech and do not change sector fundamentals by themselves.
None indicated.
None indicated.
Counterpoint
Option grants can sometimes signal retention concerns or compensation restructuring, but this filing alone does not provide evidence of distress.
Key entities
- issuerBRAINSTORM CELL THERAPEUTICS INC.
Company filing the 8-K and granting equity compensation under its 2014 Stock Incentive Plan.
- executivePeter Pitts
CEO listed as the option participant in the stock option grant notice.
